1. Home
  2. ENTO vs TIVC Comparison

ENTO vs TIVC Comparison

Compare ENTO & TIVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • TIVC
  • Stock Information
  • Founded
  • ENTO 2014
  • TIVC 2016
  • Country
  • ENTO United States
  • TIVC United States
  • Employees
  • ENTO N/A
  • TIVC N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • TIVC Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • ENTO Health Care
  • TIVC Health Care
  • Exchange
  • ENTO Nasdaq
  • TIVC Nasdaq
  • Market Cap
  • ENTO 1.9M
  • TIVC 2.1M
  • IPO Year
  • ENTO 2016
  • TIVC 2021
  • Fundamental
  • Price
  • ENTO $0.52
  • TIVC $3.95
  • Analyst Decision
  • ENTO
  • TIVC
  • Analyst Count
  • ENTO 0
  • TIVC 0
  • Target Price
  • ENTO N/A
  • TIVC N/A
  • AVG Volume (30 Days)
  • ENTO 3.2M
  • TIVC 50.7K
  • Earning Date
  • ENTO 06-17-2025
  • TIVC 05-15-2025
  • Dividend Yield
  • ENTO N/A
  • TIVC N/A
  • EPS Growth
  • ENTO N/A
  • TIVC N/A
  • EPS
  • ENTO N/A
  • TIVC N/A
  • Revenue
  • ENTO N/A
  • TIVC $516,000.00
  • Revenue This Year
  • ENTO N/A
  • TIVC N/A
  • Revenue Next Year
  • ENTO N/A
  • TIVC N/A
  • P/E Ratio
  • ENTO N/A
  • TIVC N/A
  • Revenue Growth
  • ENTO N/A
  • TIVC N/A
  • 52 Week Low
  • ENTO $0.19
  • TIVC $2.43
  • 52 Week High
  • ENTO $2.64
  • TIVC $16.08
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 69.29
  • TIVC 42.76
  • Support Level
  • ENTO $0.35
  • TIVC $3.96
  • Resistance Level
  • ENTO $0.50
  • TIVC $4.18
  • Average True Range (ATR)
  • ENTO 0.08
  • TIVC 0.25
  • MACD
  • ENTO 0.01
  • TIVC -0.02
  • Stochastic Oscillator
  • ENTO 51.85
  • TIVC 10.84

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About TIVC Tivic Health Systems Inc.

Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.

Share on Social Networks: